Literature DB >> 30517989

Immune checkpoint inhibitor-induced lymphocytic fasciitis.

Adam Rischin1, Ben Brady2, Catriona McLean1, Andrew J K Ostor2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30517989     DOI： 10.1111/imj.14126

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


× No keyword cloud information.
  4 in total

Review 1.  Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.

Authors:  Karmela Kim Chan; Cynthia Magro; Alexander Shoushtari; Charles Rudin; Veronica Rotemberg; Anthony Rossi; Cecilia Lezcano; John Carrino; David Fernandez; Michael A Postow; Arlyn Apollo; Mario E Lacouture; Anne R Bass
Journal:  Oncologist       Date:  2019-10-15

2.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

3.  Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced "Eosinophilic Fasciitis-Like" Case and a Review of the Literature.

Authors:  Christina Salamaliki; Elena E Solomou; Stamatis-Nick C Liossis
Journal:  Rheumatol Ther       Date:  2020-10-16

4.  [Myofasciitis under nivolumab treatment].

Authors:  M Krusche; U Schneider; C Geisler; S Keller; W Stenzel; S Ohrndorf
Journal:  Z Rheumatol       Date:  2021-04-22       Impact factor: 1.372
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.